GOT1 and neoplasm: The aim of the present study was to examine if a priming administration of 177Lu-octreotate 24 h before a subsequent 177Lu-octreotate administration increases the anti-tumor effect of 177Lu-octreotate in GOT1 tumor tissue in mice, compared with a single administration of the total amount of 177Lu-octreotate.